
An experimental targeted drug could provide a fresh chance for people with recurring head and neck cancer that has grown resistant to other treatments, a new clinical trial says. Ficlatuzumab used in combination with the already approved targeted drug cetuximab (Erbitux) significantly improved progression-free survival in relapsed head and neck cancer patients, according to results… read on > read on >